Why are people so against kids dying over what is ultimately statistical theory, but okay with adults.
I think you will find they have suggested this path because the adults have an alternative of Ruxolitinib (SOC) whereas children 12 years and under have no 'alternative' approved treatment as the FDA has not approved Ruxolitinib for use in children 12 years and under
Measuring Remestemcel-L against Ruxolitinib will I guess ultimately show just which one has a higher efficacy and giving the FDA something concrete to fall back upon IMO.
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-143
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.025(2.70%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.8¢ | 93.5¢ | $4.207M | 4.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 42268 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 48002 | 3 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |